Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.

MLA

Bonnefoi, Hervé, et al. “Molecular Apocrine Tumours in EORTC 10994/BIG 1-00 Phase III Study: Pathological Response after Neoadjuvant Chemotherapy and Clinical Outcomes.” British Journal of Cancer, vol. 120, no. 9, Apr. 2019, pp. 913–21. EBSCOhost, https://doi.org/10.1038/s41416-019-0420-y.

APA

Bonnefoi, H., MacGrogan, G., Poncet, C., Iggo, R., Pommeret, F., Grellety, T., Larsimont, D., Bécette, V., Kerdraon, O., Bibeau, F., Ghnassia, J.-P., Picquenot, J.-M., Thomas, J., Tille, J.-C., Slaets, L., Bodmer, A., Bergh, J., & Cameron, D. (2019). Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British Journal of Cancer, 120(9), 913–921. https://doi.org/10.1038/s41416-019-0420-y

Chicago

Bonnefoi, Hervé, Gaetan MacGrogan, Coralie Poncet, Richard Iggo, Fanny Pommeret, Thomas Grellety, Denis Larsimont, et al. 2019. “Molecular Apocrine Tumours in EORTC 10994/BIG 1-00 Phase III Study: Pathological Response after Neoadjuvant Chemotherapy and Clinical Outcomes.” British Journal of Cancer 120 (9): 913–21. doi:10.1038/s41416-019-0420-y.